SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Recent discussions around DJT are buzzing with political undertones, touching on topics from border security and immigration to trade relations. Community sentiment appears divided, with some users expressing concerns about potential impacts on American ranchers and farmers. The stock's performance and broader implications of political events remain central to the conversation.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending, with community members discussing its price action and potential. There is chatter about exchange-traded funds (ETFs), with Fidelity recently listing Solana. Some users are highlighting Solana's ecosystem and potential for future growth.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its resilient development team and utility-focused roadmap, highlighting staking opportunities and the Broke Perspective media platform. Despite market dips, the community expresses conviction, emphasizing long-term building and the potential for significant gains. Discussions also involve collaborations and support from other Solana-based projects.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to a sharp rebound after a significant decline, with community members debating whether the bottom has been reached and discussing potential catalysts like earnings and partnerships. The stock's connection to the AI infrastructure boom and recent news regarding accelerated power hookups for data centers are also fueling interest. Bullish investors are highlighting the company's long-term potential and the increasing demand for AI infrastructure.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its potential role in AI infrastructure, particularly following a $200M deal with Palantir that has sparked optimism. Community members are focused on Lumen's fiber optic network and data center connectivity, anticipating significant growth and a possible turnaround for the company. Bullish sentiment is building, with many expressing confidence in Lumen's long-term prospects within the evolving AI landscape.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as investors discuss its AI-powered biometric platform being deployed at Chicago O'Hare International Airport, sparking speculation about further airport security contracts and a potential TSA deal. The community is also focused on the company's large short interest and upcoming earnings, with some anticipating a squeeze. Bullish sentiment is fueled by the company's advancements in AI and its potential for significant growth within the national security sector.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

$BALLIN is gaining attention, with community members highlighting its availability on Phantom Wallet and touting potential gains. The conversation centers around 'bags,' 'moonshots,' and 'rocket mode,' with many suggesting it's an opportune time to get in early. Some users are expressing concerns and caution.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending amid discussions around stablecoin regulation and increasing adoption, particularly on Solana. Community members are highlighting its use in remittances, DeFi, and as a hedge against inflation in emerging markets. The meme coin BrokeCoin is also garnering attention within the USDC conversation.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

401JK is trending as community members rally around its narrative of disrupting traditional retirement plans, with many expressing bullish sentiment and highlighting the project's strong community and organic growth on the $SOL blockchain. Discussions revolve around the token's potential to reach new all-time highs and offer an alternative path to financial freedom, contrasting it with perceived flaws in the traditional 401(k) system. The community is actively promoting its message and celebrating milestones, with a focus on long-term vision rather than short-term gains.

MUSE

MUSE is trending as traders discuss its limited coin supply and potential for a squeeze, drawing comparisons to past rallies and other low-cap cryptos. Community members are actively watching volume, speculating on price movements, and highlighting its potential within the NFT space. Some believe that with increased exposure, MUSE could see significant gains.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

Taiho Pharmaceutical Co., Ltd. (Taiho) and Arcus Biosciences, Inc. (NYSE:RCUS, Arcus) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International...

Retail chatter around Arcus Biosciences picked up late Sunday after the company reported that its experimental cancer drug combination — domvanalimab and zimberelimab, given with chemotherapy — helped patients with advanced stomach and esophageal cancer live a median of 26.7 months in a mid-stage (Phase 2) study.The first overall survival results from Arm A1 of the trial will be presented on Oct. 18 at the European Society for Medical Oncology 2025 Congress, with data supporting ongoing development of the regimen in the Phase 3 STAR-221 study.According to the company’s statement, half of the patients enrolled in Arm A1 lived more than two years following treatment with domvanalimab plus zimberelimab and chemotherapy. Median progression-free survival reached 12.9 months, while confirmed objective response rate stood at 59% across all PD-L1 subgroups.&nbsp;Sun Young Rha, professor of Medical Oncology in the Department of Internal Medicine at Yonsei University College of Medicine, said the 26.7-month survival “is well beyond what would be required to demonstrate clinically meaningful benefit over standard of care.”As of March 3, the treatment demonstrated benefits across various patient groups based on PD-L1, a protein that enables tumors to evade the immune system, with approximately half of the patients still alive two years after initiating therapy. No new safety concerns were seen, and side effects were similar to what’s usually expected with immune therapy and chemotherapy.Arcus, working together with Gilead Sciences, is studying how combinations of anti-TIGIT and anti-PD-1 therapies might help people with advanced stomach and esophageal cancers.&nbsp;The ongoing Phase 3 STAR-221 trial has already enrolled over 1,000 patients around the world to see whether the domvanalimab and zimberelimab combo can perform better than current treatments using nivolumab. Both drugs are still experimental and have not yet been approved by regulators.One user said that the results showed more than a year of added survival compared with current treatments, calling it an “unprecedented” outcome for such a hard-to-treat cancer.&nbsp;<stembedurl>https://stocktwits.com/wetsalmon/message/632042158</stembedurl>Another user praised the 26-month figure as a standout result, saying it easily surpassed data from the CheckMate-649 study.<stembedurl>https://stocktwits.com/Bobes/message/632039177</stembedurl><a href="https://stocktwits.com/symbol/RCUS">Arcus Biosciences’ stock</a> has declined 2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Arcus Biosciences’ stock (RCUS) has declined 2% so far in 2025. (Photo credit: Getty Images)

Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’

The company reported strong survival data from its mid-stage trial combining domvanalimab and zimberelimab with chemotherapy in advanced stomach and esophageal cancer.

Equity

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today...

Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock?

Arcus Biosciences (RCUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +100.00% and +593.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Tops Q2 Earnings Estimates

Pacira (PCRX) delivered earnings and revenue surprises of +2.78% and -1.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today...

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

RCUS
Arcus Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RCUS News

RCUSArcus Biosciences Inc